Research Reports | Market Assessment
June 2016

Renal Cell Carcinoma | Current Treatment | EU5 | 2016

The treatment landscape for advanced/metastatic renal cell carcinoma includes well-established angiogenesis and mTOR inhibitors, many of which have broad labels allowing their use across several treatment settings. The approval of the first PD-1 inhibitor in this indication, Opdivo, has begun to have a significant impact on the treatment algorithm, particularly in later-line disease settings.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports